Clinical Trial Update: A Study of Imlunestrant Versus Standard Endocrine Therapy in Participants With Early Breast Cancer [Phase 3]

View source ↗

Summary

This is a Phase 3 clinical trial update comparing Imlunestrant with standard endocrine therapy in patients with early breast cancer.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• Imlunestrant (imlunestrant)

Snippet

Sponsor: Eli Lilly and Company | Conditions: Breast Neoplasms | Phase 3 | Status: ACTIVE_NOT_RECRUITING